KRAS and familial pancreatic carcinoma: For all of the tested cell lines including a CRC cell line (SW837), a Pancreatic cancer cell line (Mia PaCa‐2), a CRC patient‐derived cell line (PDC) (CO‐04‐0070‐PDC), and 3 NSCLC cell lines (NCI‐H23, NCI‐H1792, and NCI‐H2122), the combination treatment conferred stronger cytotoxic effects than KRAS G12C inhibition monotherapy or the FAK inhibition monotherapy (Figure 3A–F; Figure S5E, Supporting Information).